Ibustrin

Indobufen, the active ingredient in Ibustrin, is a platelet aggregation inhibitor presented as an oral tablet for oral use. It is employed to reduce the risk of clot formation in patients at risk of thromboembolic events, including those with a history of myocardial infarction or ischemic stroke.

GNH USA supplies Ibustrin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ibustrin is used in the management of cardiovascular conditions where platelet aggregation contributes to disease.

Prevention of thromboembolic events: lowers the incidence of clot‑related complications in at‑risk patients. Secondary prevention after myocardial infarction: reduces the chance of recurrent cardiac events. Prevention of ischemic stroke: diminishes the risk of stroke caused by arterial thrombosis.

Indobufen may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: mild nausea, dyspepsia or abdominal pain. - Headache: transient mild to moderate headache. - Dizziness: occasional light‑headedness.

Serious or Rare Side Effects: - Severe bleeding: gastrointestinal or intracranial hemorrhage requiring medical attention. - Thrombocytopenia: marked reduction in platelet count. - Severe allergic reaction: rash, angioedema or anaphylaxis.

When prescribing Ibustrin, clinicians should consider several safety measures to minimize risk.

Assess bleeding risk: evaluate history of hemorrhage before initiating therapy. Monitor liver function: periodic liver enzyme tests are recommended. Avoid in active peptic ulcer disease: contraindicated due to bleeding risk. Use with caution in renal impairment: dose adjustment may be required. Do not combine with other antiplatelet agents without supervision: increased bleeding potential. Store at room temperature: keep in original packaging, protect from moisture.

Indobufen can interact with other medicines, altering its antiplatelet effect or bleeding risk.

Major Interactions (Avoid): - Concurrent anticoagulants (e.g., warfarin, heparin): markedly increased bleeding risk. - Co‑administration with non‑steroidal anti‑inflammatory drugs (NSAIDs): heightened gastrointestinal bleeding.

Moderate Interactions (Monitor Closely): - Clopidogrel or other antiplatelet agents: additive antiplatelet effect, monitor for bleeding. - Selective serotonin reuptake inhibitors (SSRIs): may increase bleeding tendency, observe patient. - ACE inhibitors: potential for hypotension, monitor blood pressure.